3 Forgotten Small-Caps Quietly Winning the AI Infrastructure War

The market is in full FOMO mode right now. The Dow just hit a record high, Palantir is up 14% after hours, and Amazon crossed $3 trillion in market cap. Everyone is staring at the shiny objects. Which means the boring, under-followed corners of the market are where the actual opportunity lives. Here are three names worth a serious look.

$SLAB (Silicon Laboratories) is a mid-cap chipmaker that most retail investors couldn't pick out of a lineup. The Austin-based company makes ultra-low-power wireless chips for the Internet of Things, specifically the industrial and commercial IoT segments that don't get the AI hype treatment. With market cap sitting well under $5 billion, it flies completely under the radar of most screeners. What makes it interesting right now: the enterprise AI buildout that AWS CEO Matt Garman described as "broad adoption across financial services, healthcare, retail, and media" doesn't just need data centers. It needs a trillion edge devices feeding data into those data centers. Silicon Labs chips are in those devices. The catalyst to watch is the Q3 earnings print, where management has guided toward a recovery in the industrial IoT cycle after two brutal destocking years. If that recovery comes in above consensus, the stock has serious re-rating potential.

$CEVA (CEVA Inc.) is a semiconductor IP licensing company that makes the brains inside wireless chips, specifically the DSP cores and connectivity IP that every Bluetooth, Wi-Fi, and cellular chip needs. Think of it as the Arm Holdings of the wireless chip world, except with a market cap under $1 billion and essentially zero mainstream coverage. CEVA earns royalties every time a chip using its IP ships, which means revenue scales with volume, not capex. The AI edge inference story is the catalyst here: as more AI workloads move from cloud to device, every smartphone, wearable, and smart speaker needs more processing power at the chip level. CEVA's cores sit squarely in that path. It's not a sexy story, but it's a compounding royalty machine that the market has completely ignored.

$ICAD (iCAD Inc.) is a medical AI company that does one very specific thing: it uses artificial intelligence to detect cancer in mammograms. Market cap is roughly $100 million, which means one decent quarter could move this thing significantly. The company's ProFound AI platform is already FDA-cleared and deployed in hundreds of imaging centers across the US. The broader AI-in-healthcare narrative is well-established at this point, as evidenced by the AWS commentary around medical sector AI adoption. But iCAD is an actual revenue-generating company in that space, not a concept stock. The catalyst: any new clinical data publication showing improved detection rates, or a partnership announcement with a major health system, could be the match that lights this fuse.

None of these are household names. That's precisely the point. The entire market is staring at Palantir's 150% US growth and Amazon's $42 billion AWS quarter. The edge cases, the royalty compounders, the niche medical AI plays, those are where the asymmetry lives when the obvious trades are already crowded.

Sometimes the best investment you can make is in a ticker your group chat has never heard of.